India Sun Pharma acquires US based Concert for $576 million

Sun Pharmaceutical Industries Limited, India's largest drugmaker, said on Thursday it will acquire U.S.-based Concert Pharmaceuticals for $576 million in cash to gain access to its experimental drug for treating patchy baldness. The deal is the Indian drugmaker's biggest since its $3.2 billion acquisition of generic drugmaker Ranbaxy Laboratories Ltd in 2014, according to Refinitiv data. Sun Pharmaceutical Industries Limited, India's largest drugmaker, said on Thursday it will acquire U.S.-based Concert Pharmaceuticals for $576 million in cash to gain access to its experimental drug for treating patchy baldness. The deal is the Indian drugmaker's biggest since its $3.2 billion acquisition of generic drugmaker Ranbaxy Laboratories Ltd in 2014, according to Refinitiv data. Sun Pharma offered Concert $8 per share, representing a premium of 16% to the stock's last close. Shares of the Massachusetts-based biopharma were trading up 19.4% at $8.24 in early trading. Concert stockholders will also receive a contingent value right, based on sales milestones, entitling them to an additional amount of up to $3.50 per share of common stock in cash. The deal, which was approved by both the companies' boards, is expected to close in the first quarter this year. Concert's lead candidate, deuruxolitinib, is currently being evaluated in a latestage study as a treatment for autoimmune condition alopecia areata, which results in patchy hair loss and affects more than 300,000 people in the United States each year. Sun Pharma said its immediate focus would be to follow Concert's plan to submit a marketing application for its lead candidate to the U.S. Food and Drug Administration (FDA) in the first half of the year

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!